News

Prestige Consumer Healthcare has agreed to acquire specialty pharmaceuticals provider Akorn Operating Company’s Consumer Health business for approximately $230m. Under the terms of a definitive agreement signed by

Private equity firm Carlyle Group’s subsidiary Murano Bidco has agreed to acquire British pharmaceutical company Vectura Group for about $1.4bn (£958m). Under the terms of the acquisition, Murano

Biotechnology company Pieris Pharmaceuticals has signed a multi-programme research collaboration and licence agreement with Roche Group subsidiary Genentech. Genentech focuses on discovering and developing medicines for serious and

US-based pharmaceutical company Xeris Pharmaceuticals has agreed to acquire Strongbridge Biopharma in a stock and contingent value rights (CVRs) transaction valued at approximately $267m. Strongbridge is a commercial-stage

The Ministry of Health, Labour and Welfare (MHLW) of Japan has granted emergency use authorization for Covid-19 vaccines developed by AstraZeneca and Moderna. AstraZeneca’s Vaxzevria (ChAdOx1-S [Recombinant]), co-invented

GlaxoSmithKline (GSK) has agreed to divest the complete stake in its respiratory drug partner Innoviva for about $392m, or $12.25 per share. Under the terms of a definitive

Exscientia has expanded its partnership with Bristol-Myers Squibb (BMS) to leverage artificial intelligence (AI) to discover small molecule drug candidates across oncology and immunology, among other therapeutic areas.

As part of the agreement, BMS will pay $200m upfront to Agenus, which is also eligible for up to $1.36bn in development, regulatory and commercial milestone payments and

The agreement also covers additional payments of up to $57.5m contingent on future performance. Charles River expects the deal to boost its gene therapy capabilities for viral vectors